Form 4: BioXcel Therapeutics CFO Reports Stock Transactions
SEC Form 4
Richard Steinhart, CFO of BioXcel Therapeutics, reports the vesting and acquisition of common stock through restricted stock units.
Summary
- Richard Steinhart, the Chief Financial Officer of BioXcel Therapeutics, Inc. (BTAI), filed a Form 4 detailing changes in beneficial ownership.
- On March 14, 2025, 31 shares of common stock were acquired through the vesting of restricted stock units (RSUs).
- On March 15, 2025, an additional 34 shares of common stock were acquired through the vesting of RSUs.
- Following these transactions, Steinhart directly owns 1,373 shares of BioXcel Therapeutics common stock.
- The RSUs vest in installments, contingent upon Steinhart's continued employment with the company.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to stock transactions by an executive, which doesn't inherently indicate positive or negative sentiment about the company's prospects.
Positives
- The vesting of RSUs and subsequent acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's financial performance or future prospects.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's sentiment and potential future performance.
Stakeholder Impact
- The transactions have a minor impact on shareholders, reflecting a slight increase in insider ownership.
Key Dates
| Date | Description |
|---|---|
| March 14, 2022 | Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| March 15, 2023 | Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| March 14, 2025 | Transaction date: 31 shares of common stock acquired through RSU vesting. |
| March 15, 2025 | Transaction date: 34 shares of common stock acquired through RSU vesting. |
| March 17, 2025 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.